近日,美国食品和药物管理局批准依达拉奉(Radicava,田边三菱制药用于延缓肌萎缩侧索硬化(ALS)患者的神经功能下降。氧化应激是ALS发作和进展的很可能的因素,而依达拉奉(吡唑啉酮类化合物)是一种自由基清除剂,可以减轻氧化应激效应。这种药物于2015年在日本和韩国首次被批准治疗ALS。FDA药物评价与研究中心神经学产品部副主任表示:在听说edara- Recently, the U.S. Food and Drug Administration approved Edaravone (Tanabe) to delay the decline in neurological function in patients with amyotrophic lateral sclerosis (ALS) .Oxidative stress is a very likely factor in the onset and progression of ALS , While edaravone (a pyrazolone compound) is a free-radical scavenger that reduces oxidative stress effects and was first approved for treatment of ALS in Japan and South Korea in 2015. FDA Evaluation and Research Deputy Director of Neurology Products Department said: I heard edara-